Sergio Teruya

1.4k total citations
59 papers, 742 citations indexed

About

Sergio Teruya is a scholar working on Molecular Biology, Nephrology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Sergio Teruya has authored 59 papers receiving a total of 742 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 27 papers in Nephrology and 16 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Sergio Teruya's work include Amyloidosis: Diagnosis, Treatment, Outcomes (36 papers), Parathyroid Disorders and Treatments (24 papers) and Erythropoietin and Anemia Treatment (8 papers). Sergio Teruya is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (36 papers), Parathyroid Disorders and Treatments (24 papers) and Erythropoietin and Anemia Treatment (8 papers). Sergio Teruya collaborates with scholars based in United States, Japan and Australia. Sergio Teruya's co-authors include Mathew S. Maurer, Stephen Helmke, Julissa Alvarez, Jeffeny De Los Santos, Alexi Vasbinder, Douglas Leedy, Maria L. Cornellier, Wayne C. Levy, Wahida Karmally and Donna Mancini and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Sergio Teruya

51 papers receiving 724 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sergio Teruya United States	17	397	229	209	170	105	59	742
Nuno Cortez‐Dias Portugal	15	322 0.8×	320 1.4×	82 0.4×	36 0.2×	45 0.4×	68	774
Nadezda Koleganova Germany	17	132 0.3×	101 0.4×	312 1.5×	74 0.4×	39 0.4×	30	803
Marvin Grieff United States	15	149 0.4×	68 0.3×	363 1.7×	87 0.5×	89 0.8×	19	781
Tarak Srivastava United States	13	58 0.1×	58 0.3×	272 1.3×	128 0.8×	105 1.0×	23	622
Christopher Laing United Kingdom	10	167 0.4×	137 0.6×	178 0.9×	73 0.4×	14 0.1×	15	811
John Vassiliadis United States	16	159 0.4×	37 0.2×	411 2.0×	159 0.9×	146 1.4×	25	957
Gérard Maruani France	13	53 0.1×	147 0.6×	284 1.4×	63 0.4×	134 1.3×	24	637
Naohiko Imai Japan	12	190 0.5×	59 0.3×	188 0.9×	40 0.2×	24 0.2×	46	499
Solmaz Assa Netherlands	15	90 0.2×	150 0.7×	194 0.9×	49 0.3×	21 0.2×	36	542
Ravinder Sodi United Kingdom	14	99 0.2×	57 0.2×	117 0.6×	103 0.6×	28 0.3×	28	516

Countries citing papers authored by Sergio Teruya

Since Specialization

Citations

This map shows the geographic impact of Sergio Teruya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergio Teruya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergio Teruya more than expected).

Fields of papers citing papers by Sergio Teruya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sergio Teruya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergio Teruya. The network helps show where Sergio Teruya may publish in the future.

Co-authorship network of co-authors of Sergio Teruya

This figure shows the co-authorship network connecting the top 25 collaborators of Sergio Teruya. A scholar is included among the top collaborators of Sergio Teruya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sergio Teruya. Sergio Teruya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Teruya, Sergio, et al.. (2025). Using Patient-Reported Outcomes to Assess Transthyretin Amyloid Cardiomyopathy Progression in Patients Treated With Disease-Modifying Therapy. JACC Heart Failure. 13(9). 102553–102553.

Sperry, Brett W., Ahmad Masri, Prem Soman, et al.. (2025). Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study. Journal of the American Heart Association. 14(23). e042530–e042530.

Teruya, Sergio, et al.. (2025). Impact of autonomic dysfunction on cardiovascular outcomes among patients with ATTR cardiomyopathy: insights from the COMPASS-31. Amyloid. 32(4). 314–323.

Lang, Frederick, et al.. (2024). Sodium–Glucose Cotransporter 2 Inhibitors for Transthyretin Amyloid Cardiomyopathy: Analyses of Short-Term Efficacy and Safety. European Journal of Heart Failure. 26(4). 938–947. 23 indexed citations

Teruya, Sergio, et al.. (2024). Outpatient Worsening of Heart Failure and Mortality in Transthyretin Amyloid Cardiomyopathy. European Journal of Heart Failure. 27(12). 2961–2970. 5 indexed citations

Chan, Nicholas, Andrew J. Einstein, Sergio Teruya, et al.. (2024). The Impact of Active Ascertainment on Sex-Specific Differences in the Prevalence and Phenotype of Transthyretin Cardiac Amyloidosis: The Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations Study. The American Journal of Cardiology. 237. 60–64.

Fine, Denise, Stephen Helmke, Farbod Raiszadeh, et al.. (2023). Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. Journal of the American Heart Association. 12(15). e028973–e028973. 17 indexed citations

Chan, Nicholas, Sergio Teruya, Jeffeny De Los Santos, et al.. (2023). Abstract 14362: The Columbia Score Predicts Incident Atrial Fibrillation and Flutter in Patients With Transthyretin Cardiac Amyloidosis. Circulation. 148(Suppl_1). 1 indexed citations

Poterucha, Timothy J., Farbod Raiszadeh, Sergio Teruya, et al.. (2022). Relation of Body Mass Index to Transthyretin Cardiac Amyloidosis Particularly in Black and Hispanic Patients (from the SCAN-MP Study). The American Journal of Cardiology. 177. 116–120. 4 indexed citations

10.

Teruya, Sergio, et al.. (2022). Central Obesity Is Associated With an Increased Rate of Multisite Pain in Older Adults. Frontiers in Public Health. 10. 735591–735591. 1 indexed citations

11.

Batra, Jaya, Hannah Rosenblum, Ersilia M. DeFilippis, et al.. (2020). Sex Differences in the Phenotype of Transthyretin Cardiac Amyloidosis Due to Val122Ile Mutation: Insights from Noninvasive Pressure–Volume Analysis. Journal of Cardiac Failure. 27(1). 67–74. 20 indexed citations

12.

Brannagan, Thomas H., et al.. (2020). Early-Onset of Transthyretin Amyloidosis in a Young Afro-Caribbean Woman With Thr60Ala Mutation. SHILAP Revista de lepidopterología. 2(13). 2063–2067. 3 indexed citations

13.

Driggin, Elissa, et al.. (2019). MODIFIED BODY MASS INDEX IN TRANSTHYRETIN CARDIAC AMYLOIDOSIS: ASSOCIATION WITH OUTCOMES AND THE CLINICAL PHENOTYPE. Journal of the American College of Cardiology. 73(9). 743–743.

14.

Teruya, Sergio, et al.. (2019). FUNCTIONAL CAPACITY MEASURED BY THE SHORT PHYSICAL PERFORMANCE BATTERY (SPPB) AND NOT CARDIAC PARAMETERS ARE INDEPENDENTLY ASSOCIATED WITH QUALITY OF LIFE IN PATIENTS WITH TRANSTHYRETIN CARDIOMYOPATHY. Journal of the American College of Cardiology. 73(9). 763–763. 1 indexed citations

15.

Rubin, Jonah, Julissa Alvarez, Sergio Teruya, et al.. (2017). Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier?. Amyloid. 24(4). 224–228. 50 indexed citations

16.

Helmke, Stephen, et al.. (2014). The myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with AL cardiac amyloidosis. Amyloid. 22(1). 61–66. 52 indexed citations

17.

Green, Philip, Benson A. Babu, Sergio Teruya, et al.. (2013). Impact of Epoetin Alfa on Left Ventricular Structure, Function, and Pressure Volume Relations as Assessed by Cardiac Magnetic Resonance: The Heart Failure Preserved Ejection Fraction (HFPEF) Anemia Trial. Congestive Heart Failure. 19(4). 172–179. 3 indexed citations

18.

Maurer, Matthew J., et al.. (2011). CHANGES IN THE TYPE OF CARDIAC AMYLOIDOSIS DIAGNOSED AT A TERTIARY REFERRAL CENTER: ONE IMPACT OF AN AGING POPULATION. Journal of the American College of Cardiology. 57(14). E247–E247. 1 indexed citations

19.

Altincatal, Arman, Robert B. MacArthur, Sergio Teruya, Stephen Helmke, & Matthew J. Maurer. (2011). A Dosing Algorithm for Erythropoietin Alpha in Older Adults with Heart Failure and a Preserved Ejection Fraction. Cardiovascular Therapeutics. 31(2). 92–99. 2 indexed citations

20.

Teruya, Sergio, et al.. (2011). Blood Volume Measurements in Patients With Heart Failure and a Preserved Ejection Fraction: Implications for Diagnosing Anemia. Congestive Heart Failure. 17(1). 14–18. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact